tiprankstipranks
Trending News
More News >
bluebird bio (BLUE)
NASDAQ:BLUE
US Market

Bluebird Bio (BLUE) Stock Forecast & Price Target

Compare
2,840 Followers
See the Price Targets and Ratings of:

BLUE Analyst Ratings

Moderate Buy
1Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Bluebird
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BLUE Stock 12 Month Forecast

Average Price Target

$8.00
▲(60.00%Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Bluebird Bio in the last 3 months. The average price target is $8.00 with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 60.00% change from the last price of $5.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","32":"$32","10.25":"$10.25","17.5":"$17.5","24.75":"$24.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,10.25,17.5,24.75,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.05,4.3538461538461535,4.657692307692308,4.961538461538462,5.265384615384615,5.569230769230769,5.873076923076923,6.176923076923077,6.480769230769231,6.7846153846153845,7.088461538461539,7.392307692307693,7.696153846153846,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.05,4.3538461538461535,4.657692307692308,4.961538461538462,5.265384615384615,5.569230769230769,5.873076923076923,6.176923076923077,6.480769230769231,6.7846153846153845,7.088461538461539,7.392307692307693,7.696153846153846,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.05,4.3538461538461535,4.657692307692308,4.961538461538462,5.265384615384615,5.569230769230769,5.873076923076923,6.176923076923077,6.480769230769231,6.7846153846153845,7.088461538461539,7.392307692307693,7.696153846153846,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.97,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.3,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.19,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.41,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$8.00Average Price Target$8.00Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BLUE
TipRanks AITipRanks
Not Ranked
TipRanks
$4.5
Sell
-10.00%
Downside
Reiterated
05/17/25
Bluebird Bio's overall score reflects significant financial challenges, including unprofitable operations and negative equity. While technical analysis shows short-term momentum, long-term trends are less favorable. The negative P/E ratio underscores valuation concerns, and the lack of a dividend yield makes it less attractive for income investors.
Barclays Analyst forecast on BLUE
Gena WangBarclays
Barclays
$8
Buy
60.00%
Upside
Reiterated
05/15/25
Barclays Remains a Buy on Bluebird Bio (BLUE)
William Blair Analyst forecast on BLUE
Sami CorwinWilliam Blair
William Blair
Hold
Reiterated
02/21/25
Cautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones
Wells Fargo Analyst forecast on BLUE
Yanan ZhuWells Fargo
Wells Fargo
$40$5
Hold
0.00%
Upside
Reiterated
02/21/25
bluebird bio (BLUE) PT Lowered to $5 at Wells FargoWells Fargo analyst Yanan Zh lowered the price target on bluebird bio (NASDAQ: BLUE) to $5.00 (from $40.00) while maintaining a Equal Weight rating.
RBC Capital Analyst forecast on BLUE
Luca IssiRBC Capital
RBC Capital
$80$8
Hold
60.00%
Upside
Reiterated
01/07/25
Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'
Leerink Partners Analyst forecast on BLUE
Mani ForooharLeerink Partners
Leerink Partners
$1$10
Hold
100.00%
Upside
Reiterated
01/03/25
Analysts Offer Insights on Healthcare Companies: Cencora (NYSE: COR) and Bluebird Bio (NASDAQ: BLUE)
Bank of America Securities Analyst forecast on BLUE
Jason GerberryBank of America Securities
Bank of America Securities
$60$10
Hold
100.00%
Upside
Downgraded
11/15/24
Bluebird Bio downgraded to Neutral from Buy at BofABluebird Bio downgraded to Neutral from Buy at BofA
Oppenheimer Analyst forecast on BLUE
Mark BreidenbachOppenheimer
Oppenheimer
Hold
Reiterated
08/15/24
Oppenheimer reiterates Perform Rating on bluebird bio (BLUE)Oppenheimer analyst Mark Breidenbach reiterated a Perform rating on bluebird bio (NASDAQ: BLUE).
Morgan Stanley Analyst forecast on BLUE
Jeffrey HungMorgan Stanley
Morgan Stanley
$100
Hold
1900.00%
Upside
Reiterated
08/14/24
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BLUE
TipRanks AITipRanks
Not Ranked
TipRanks
$4.5
Sell
-10.00%
Downside
Reiterated
05/17/25
Bluebird Bio's overall score reflects significant financial challenges, including unprofitable operations and negative equity. While technical analysis shows short-term momentum, long-term trends are less favorable. The negative P/E ratio underscores valuation concerns, and the lack of a dividend yield makes it less attractive for income investors.
Barclays Analyst forecast on BLUE
Gena WangBarclays
Barclays
$8
Buy
60.00%
Upside
Reiterated
05/15/25
Barclays Remains a Buy on Bluebird Bio (BLUE)
William Blair Analyst forecast on BLUE
Sami CorwinWilliam Blair
William Blair
Hold
Reiterated
02/21/25
Cautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones
Wells Fargo Analyst forecast on BLUE
Yanan ZhuWells Fargo
Wells Fargo
$40$5
Hold
0.00%
Upside
Reiterated
02/21/25
bluebird bio (BLUE) PT Lowered to $5 at Wells FargoWells Fargo analyst Yanan Zh lowered the price target on bluebird bio (NASDAQ: BLUE) to $5.00 (from $40.00) while maintaining a Equal Weight rating.
RBC Capital Analyst forecast on BLUE
Luca IssiRBC Capital
RBC Capital
$80$8
Hold
60.00%
Upside
Reiterated
01/07/25
Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'
Leerink Partners Analyst forecast on BLUE
Mani ForooharLeerink Partners
Leerink Partners
$1$10
Hold
100.00%
Upside
Reiterated
01/03/25
Analysts Offer Insights on Healthcare Companies: Cencora (NYSE: COR) and Bluebird Bio (NASDAQ: BLUE)
Bank of America Securities Analyst forecast on BLUE
Jason GerberryBank of America Securities
Bank of America Securities
$60$10
Hold
100.00%
Upside
Downgraded
11/15/24
Bluebird Bio downgraded to Neutral from Buy at BofABluebird Bio downgraded to Neutral from Buy at BofA
Oppenheimer Analyst forecast on BLUE
Mark BreidenbachOppenheimer
Oppenheimer
Hold
Reiterated
08/15/24
Oppenheimer reiterates Perform Rating on bluebird bio (BLUE)Oppenheimer analyst Mark Breidenbach reiterated a Perform rating on bluebird bio (NASDAQ: BLUE).
Morgan Stanley Analyst forecast on BLUE
Jeffrey HungMorgan Stanley
Morgan Stanley
$100
Hold
1900.00%
Upside
Reiterated
08/14/24
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bluebird Bio

1 Month
xxx
Success Rate
10/23 ratings generated profit
43%
Average Return
-0.27%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 43.48% of your transactions generating a profit, with an average return of -0.27% per trade.
3 Months
xxx
Success Rate
14/23 ratings generated profit
61%
Average Return
+4.85%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +4.85% per trade.
1 Year
Gena WangBarclays
Success Rate
10/23 ratings generated profit
43%
Average Return
+20.57%
reiterated a buy rating 14 days ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 43.48% of your transactions generating a profit, with an average return of +20.57% per trade.
2 Years
xxx
Success Rate
10/23 ratings generated profit
43%
Average Return
+26.44%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 43.48% of your transactions generating a profit, with an average return of +26.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BLUE Analyst Recommendation Trends

Rating
Nov 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
5
4
3
2
2
Buy
0
0
0
0
0
Hold
9
8
11
7
6
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
15
13
15
9
8
In the current month, BLUE has received 2 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. BLUE average Analyst price target in the past 3 months is 8.00.
Each month's total comprises the sum of three months' worth of ratings.

BLUE Financial Forecast

BLUE Earnings Forecast

The previous quarter’s earnings for BLUE were -$2.98.
The previous quarter’s earnings for BLUE were -$2.98.

BLUE Sales Forecast

The previous quarter’s earnings for BLUE were $38.71M.
The previous quarter’s earnings for BLUE were $38.71M.

BLUE Stock Forecast FAQ

What is BLUE’s average 12-month price target, according to analysts?
Based on analyst ratings, bluebird bio’s 12-month average price target is 8.00.
    What is BLUE’s upside potential, based on the analysts’ average price target?
    bluebird bio has 60.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BLUE a Buy, Sell or Hold?
          bluebird bio has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is bluebird bio’s price target?
            The average price target for bluebird bio is 8.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $8.00 ,the lowest forecast is $8.00. The average price target represents 60.00% Increase from the current price of $5.
              What do analysts say about bluebird bio?
              bluebird bio’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of BLUE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis